PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)

出版年份 2020 全文链接

标题

作者

关键词

Alirocumab, atherosclerotic cardiovascular disease, lipoprotein(a), apolipoprotein (a) kinetics, proprotein convertase subtilisin/kexin type 9

出版物

Volume 107, Issue -, Pages 154221

出版商

Elsevier BV

发表日期

2020-03-31

DOI

10.1016/j.metabol.2020.154221

联系作者

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started